Core Points - Transgene has appointed Emmanuelle Quilès as an independent Director to its Board of Directors, succeeding Philippe Archinard, who is retiring [1][3] - Emmanuelle Quilès brings over 25 years of experience in strategic leadership roles within the global pharmaceutical industry, previously serving as Worldwide Vice President at Janssen Global Commercial Strategy Organization [2][5] - The appointment is effective from July 9, 2025, and Quilès will serve the remainder of Archinard's term until the 2026 Annual Shareholders' Meeting [3] Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes TG4050, TG4001, BT-001, and TG6050 [8] - The company utilizes its myvac® platform for individualized therapeutic vaccines and the Invir.IO® platform for multifunctional oncolytic viruses [9][10] - Transgene's clinical-stage programs are aimed at providing targeted immunotherapies, with a focus on precision medicine [8][9]

Core Insights - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with a particular emphasis on individualized therapies [2][3] - The company announced upcoming meetings with institutional investors and leaders in the biotechnology ecosystem to discuss its clinical data and treatment landscape for head and neck cancers [1][6] Company Overview - Transgene's lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in patients for adjuvant treatment of head and neck cancers [2] - The company also has a portfolio that includes TG4001 for HPV-positive cancers and two oncolytic viruses, BT-001 and TG6050, based on the Invir.IO® viral backbone [2] Technological Innovations - The myvac® platform allows for the creation of personalized virus-based immunotherapies tailored to individual patient mutations, utilizing AI capabilities from partner NEC [3] - Transgene is leveraging its expertise in viral vector engineering to develop a new generation of multifunctional oncolytic viruses through its proprietary Invir.IO® platform [4] Upcoming Events - Transgene will participate in several key industry events, including the BIO International Convention on June 16, 2025, in Boston, and the International Neoantigen Summit on June 24, 2025, in Amsterdam [6]

Core Viewpoint - Transgene is set to present positive clinical data for its individualized neoantigen cancer vaccine, TG4050, at the 2025 ASCO Annual Meeting, highlighting advancements in cancer immunotherapy [1][2]. Company Overview - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with a clinical-stage portfolio that includes TG4050, TG4001, BT-001, and TG6050 [3]. - TG4050 is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in treating head and neck cancers [3]. - The company utilizes its proprietary Invir.IO® platform to engineer multifunctional oncolytic viruses, enhancing its viral vector capabilities [5]. Upcoming Event - A live webcast discussing the latest findings on TG4050 will occur on June 6, 2025, featuring Transgene's management and Prof. Christian Ottensmeier, focusing on the treatment landscape for early-stage HPV-negative head and neck cancer [2].

Core Points - The Combined Ordinary and Extraordinary General Meeting of Transgene's shareholders took place on May 15, 2025, where various resolutions were voted on and approved [1][2] - The meeting resulted in the renewal of the terms of office for several Board Members, maintaining a diverse and independent Board composition [3][4] - A share capital reduction was approved, decreasing the par value of shares from €0.50 to €0.30, along with the delegation of authority for a potential reverse stock split [5] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [7] - The lead asset, TG4050, is an individualized therapeutic vaccine aimed at head and neck cancers, showcasing the company's innovative approach to precision medicine [8] - Transgene utilizes its proprietary Invir.IO® platform to engineer multifunctional oncolytic viruses, enhancing its capabilities in viral vector technology [9]